Abiopharma

🔍 Lee Chan Henry (Executive)

Company: BeOne Medicines Ltd. (ONC)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 202 shares of American Depositary Shares at $194.47 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 202.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 266 shares of American Depositary Shares at $213.32 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 468.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 196 shares of American Depositary Shares at $159.03 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 664.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 664 shares of American Depositary Shares at $331.76 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-01-07 | Code: H | shares_owned_after: 223,106.00
• Sold 2,626 shares of Share Option (Right to Buy) at $14.96 per share (Derivative)
  Date: 2026-01-07 | Code: M | Expires: 2032-08-04 | equity_swap_involved: 0 | shares_owned_after: 30,446.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 3,458 shares of Share Option (Right to Buy) at $16.41 per share (Derivative)
  Date: 2026-01-07 | Code: M | Expires: 2033-06-14 | equity_swap_involved: 0 | shares_owned_after: 97,019.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 2,548 shares of Share Option (Right to Buy) at $12.23 per share (Derivative)
  Date: 2026-01-07 | Code: M | Expires: 2034-06-04 | equity_swap_involved: 0 | shares_owned_after: 118,118.00 | transaction_form_type: 4 | Footnotes: F3, F6

Footnotes:

• F1: Each American Depositary Share represents 13 Ordinary Shares.
• F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
• F3: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
• F4: These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
• F5: These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
• F6: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.